Biotech · Private company · Juno Beach, FL, US
Emmune, Inc
Track this companyFree. Adds Emmune, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards8
- PK, tolerability, and toxicology studies for eCD4-Ig as a long-acting recombinant protein therapeuticFiscal year 2026 · $299.4KNIH RePORTER 1R44AI197364-01 · fetched Nov 12, 2026
- Non-viral gene therapy to treat and prevent atherosclerosisFiscal year 2026 · $299.7KNIH RePORTER 1R44HL184837-01A1 · fetched Nov 12, 2026
- IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeuticFiscal year 2025 · $300KNIH RePORTER 1R43AI191927-01 · fetched Nov 12, 2026
- Non-viral gene therapy with eCD4-IgFiscal year 2025 · $917.3KNIH RePORTER 1R56AI189343-01 · fetched Nov 12, 2026
- Process development for manufacturing eCD4-IgFiscal year 2025 · $1MNIH RePORTER 4R44AI170285-02 · fetched Nov 12, 2026
- SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sitesFiscal year 2025 · $1MNIH RePORTER 5R44AI170392-04 · fetched Nov 12, 2026
- Glycoengineering eCD4-IgFiscal year 2024 · $974.7KNIH RePORTER 5R44AI165255-04 · fetched Nov 12, 2026
- SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sitesFiscal year 2024 · $1MNIH RePORTER 5R44AI170392-03 · fetched Nov 12, 2026